Clinical Trial Update: Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating switching from prostaglandin monotherapy to omidenepag isopropyl for prostaglandin-associated peri-orbitopathy in glaucoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Suspect
• Normal Tension Glaucoma
• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Omidenepag isopropyl (omidenepag isopropyl)

Snippet

Sponsor: Santen Pharmaceutical Asia Pte. Ltd. | Conditions: Normal Tension Glaucoma, Primary Open-angle Glaucoma | Phase 4 | Status: UNKNOWN